Overview

A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism

Status:
Terminated
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects on serum testosterone after 4 weeks of subcutaneous (SC) dose administration, with different doses and dosing frequencies of TAK-448 to overweight/obese males with hypogonadotropic hypogonadism.
Phase:
Phase 2
Details
Lead Sponsor:
Takeda